Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum Arch Biopartners Inc ACHFF


Primary Symbol: V.ARCH

Arch Biopartners Inc. is a portfolio-based biotechnology company focused on the development of technologies that have the potential to make a medical or commercial impact. The Company is focused on the clinical development of its drug platform in targeting dipeptidase-1 (DPEP-1) mediated organ inflammation in the lungs, liver and kidneys. Its lead drug candidate is LSALT Peptide (Metablok... see more

TSXV:ARCH - Post Discussion

Arch Biopartners Inc > Pumped & Dumped
View:
Post by williepoker on Dec 22, 2021 10:47am

Pumped & Dumped

Pump and dump
Comment by stocksarefun on Dec 22, 2021 10:53am
get out of here
Comment by GoldenArm on Dec 22, 2021 2:04pm
Holding pattern can make people jittery because they never did any research or know anything about the company.  You're either a day trader or a speculator and just looking for the quick buck. The fast rise to $5/shr brought a lot of players into the game but the slow hand will win in the end and that is coming very soon.
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities